Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: November 2, 2009
Last updated: October 13, 2015
Last verified: October 2015